Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Predicative biomarkers of response to immunotherapy in STS

Brian Van Tine • 4 Jun 2023
ASCO 2023
Sarcoma Antibodies Cabozantinib Checkpoint Inhibitors Ipilimumab Nivolumab

Brian Van Tine, MD, PhD, Washington University, St. Louis, MO, comments on biomarker research in the Phase II trial (NCT04551430) of cabozantinib with nivolumab and ipilimumab in patients with metastatic soft tissue sarcoma (STS). Analysis of patient biopsies with RNA-seq will enable the identification of biomarkers that will enable clinicians to find patients who will respond treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Brian Van Tine

0:54
What does the future hold for CAR T-cells in sarcoma management?
Brian Van Tine • 4 Jun 2023
0:50
SPEARHEAD-1: afamitresgene autoleucel in advanced synovial sarcoma
Brian Van Tine • 4 Jun 2023
0:57
Cabozantinib with checkpoint inhibition in soft tissue sarcoma
Brian Van Tine • 4 Jun 2023
0:55
Key data in sarcoma presented at ASCO 2022
Brian Van Tine • 4 Jun 2022

Related Videos

0:51
Enhanced NK-cells in stage 4 sarcoma treatment
Vaishali Kumar • 8 Apr 2024
1:12
Predictive biomarkers for checkpoint inhibitors in sarcomas
Nadia Omelchenko • 8 Apr 2024
1:26
SAINT and LINNOVATE: combining ICIs and chemotherapy in advanced STC
Nadia Omelchenko • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals